BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37248526)

  • 1. Validation of the ALBI-TAE model and comparison of seven scoring systems for predicting survival outcome in patients with intermediate-stage hepatocellular carcinoma undergoing chemoembolization.
    Bannangkoon K; Hongsakul K; Tubtawee T
    Cancer Imaging; 2023 May; 23(1):51. PubMed ID: 37248526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of models to predict prognosis in patients with advanced hepatocellular carcinoma treated with TACE combined with apatinib.
    Sun F; Liu KC; Ul Ain Q; Lu D; Zhou CZ; Xiao JK; Zhang XM; Zhang ZF; Cheng DL; He YS; Lv WF
    BMC Gastroenterol; 2024 Apr; 24(1):129. PubMed ID: 38589828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
    Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
    Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    Jia KF; Wang H; Yu CL; Yin WL; Zhang XD; Wang F; Sun C; Shen W
    Hepatobiliary Pancreat Dis Int; 2023 Oct; 22(5):490-497. PubMed ID: 35260337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC.
    Zhao S; Zhang T; Li H; Wang M; Xu K; Zheng D; Du X; Liu L
    Ann Transl Med; 2020 Apr; 8(8):538. PubMed ID: 32411761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.
    Pinato DJ; Sharma R; Allara E; Yen C; Arizumi T; Kubota K; Bettinger D; Jang JW; Smirne C; Kim YW; Kudo M; Howell J; Ramaswami R; Burlone ME; Guerra V; Thimme R; Ishizuka M; Stebbing J; Pirisi M; Carr BI
    J Hepatol; 2017 Feb; 66(2):338-346. PubMed ID: 27677714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients.
    Jia K; Yin W; Gao Z; Shen W; Wang F; Xie S; Li M; Lv R
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):461-470. PubMed ID: 36827534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
    Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
    World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function.
    Müller L; Hahn F; Mähringer-Kunz A; Stoehr F; Gairing SJ; Foerster F; Weinmann A; Galle PR; Mittler J; Pinto Dos Santos D; Pitton MB; Düber C; Kloeckner R
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis.
    Mishra G; Majeed A; Dev A; Eslick GD; Pinato DJ; Izumoto H; Hiraoka A; Huo TI; Liu PH; Johnson PJ; Roberts SK
    J Gastrointest Cancer; 2023 Jun; 54(2):420-432. PubMed ID: 35635637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival Analysis Using Albumin-Bilirubin (ALBI) Grade for Patients Treated with Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Young LB; Tabrizian P; Sung J; Biederman D; Bishay VL; Ranade M; Patel RS; Nowakowski FS; Fischman AM; Lookstein RA; Kim E
    J Vasc Interv Radiol; 2022 May; 33(5):510-517.e1. PubMed ID: 35150838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.
    Izumoto H; Hiraoka A; Ishimaru Y; Murakami T; Kitahata S; Ueki H; Aibiki T; Okudaira T; Miyamoto Y; Yamago H; Iwasaki R; Tomida H; Mori K; Kishida M; Tsubouchi E; Miyata H; Ninomiya T; Kawasaki H; Hirooka M; Matsuura B; Abe M; Hiasa Y; Michitaka K; Kudo M
    Oncology; 2017; 93 Suppl 1():120-126. PubMed ID: 29258105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
    Zhong BY; Ni CF; Ji JS; Yin GW; Chen L; Zhu HD; Guo JH; He SC; Deng G; Zhang Q; Li PC; Yu H; Song JJ; Teng GJ
    J Vasc Interv Radiol; 2019 Mar; 30(3):330-338. PubMed ID: 30819473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization.
    Liu Y; Cheng C; Zhou H; Hu S; Wang H; Xie Q; Lei L; Wang P; Liu G; Hu H
    Bull Cancer; 2021 Oct; 108(10):931-939. PubMed ID: 34247763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma.
    Carling U; Røsok B; Line PD; Dorenberg EJ
    Acta Radiol; 2019 Jun; 60(6):702-709. PubMed ID: 30205701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
    Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
    World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Hansmann J; Evers MJ; Bui JT; Lokken RP; Lipnik AJ; Gaba RC; Ray CE
    J Vasc Interv Radiol; 2017 Sep; 28(9):1224-1231.e2. PubMed ID: 28688815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
    Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
    Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.